Akari Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:CLA Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
06 Mar 25	Buy€138,509	Abizer Gaslightwala	Individual	133,928	€1.03
06 Mar 25	Buy€4,617	James Neal	Individual	4,464	€1.03
06 Mar 25	Buy€461,699	Raymond Prudo-Chlebosz	Individual	446,428	€1.03
06 Mar 25	Buy€46,169	Robert Bazemore	Individual	44,642	€1.03
06 Mar 25	Buy€923,400	Hoyoung Huh	Individual	892,857	€1.03

Insider Trading Volume

Insider Buying: CLA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CLA?
Owner Type	Number of Shares	Ownership Percentage
Institutions	330,508	1.33%
Private Companies	400,383	1.62%
General Public	9,577,792	38.7%
Individual Insiders	14,449,874	58.4%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 275%.

Top Shareholders

Top 25 shareholders own 61.31% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
19.4%	Hoyoung Huh	4,805,311	€6.8m	22.8%	no data
12.4%	Samir Patel	3,076,703	€4.4m	15.2%	no data
10.1%	Raymond Prudo-Chlebosz	2,504,345	€3.5m	21.7%	no data
4.29%	Matthew Nachtrab	1,061,007	€1.5m	0%	no data
4.29%	Charles Theofilos	1,061,007	€1.5m	0%	no data
3.82%	Thomas Mollick	944,910	€1.3m	0%	no data
2.07%	Sandip Patel	512,107	€724.2k	0%	no data
1.62%	RPC Pharma Limited	400,383	€566.2k	0%	no data
0.84%	Rachelle Jacques	207,642	€293.6k	234%	no data
0.73%	Abizer Gaslightwala	181,428	€256.6k	418%	no data
0.59%	Palo Alto Investors LP	146,024	€206.5k	0%	0.03%
0.35%	Omnia Family Wealth, LLC	87,628	€123.9k	0%	0.05%
0.18%	Robert Bazemore	44,642	€63.1k	0%	no data
0.095%	Cerity Partners LLC	23,643	€33.4k	0%	no data
0.095%	Renaissance Technologies LLC	23,465	€33.2k	29.9%	no data
0.083%	James Neal	20,572	€29.1k	69.9%	no data
0.074%	Cresset Asset Management, LLC	18,408	€26.0k	0%	no data
0.053%	Catalina Capital Group, LLC	13,105	€18.5k	0%	0.01%
0.04%	Donald Williams	10,000	€14.1k	0%	no data
0.04%	Donald Williams	10,000	€14.1k	0%	no data
0.04%	Michael Grissinger	10,000	€14.1k	0%	no data
0.04%	Accent Capital Management LLC	10,000	€14.1k	0%	0.01%
0.025%	Bg Fund Management Luxembourg S.A.	6,114	€8.6k	0%	no data
0.0065%	RiverNorth Capital Management, LLC	1,611	€2.3k	0%	no data
0.00081%	Torsten Hombeck	200	€283.6	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/23 19:35
End of Day Share Price	2025/03/21 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akari Therapeutics, Plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners
Madhu Kumar	B. Riley Securities, Inc.
Arlinda Lee	Canaccord Genuity